GT Biopharma progresses GTB-3650 Phase 1 trial to Cohort 2 after successful initial human dosing and early signs of immune activation. Forward-looking statements in this press release highlight future projections and market expectations. Readers should be aware of potential risks and uncertainties outlined in the company’s SEC filings. Despite the challenges, the company remains committed to advancing their innovative biopharmaceutical developments. Stay updated on the latest advancements in biopharma by referring to GT Biopharma’s official filings with the Securities and Exchange Commission.
Read more from finance.yahoo.com
